Phase 1 Myeloproliferative Neoplasm Clinical Trials
21 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 21 trials
Recruiting
Phase 1
A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms
Myelofibrosis (MF)Polycythemia Vera (PV)Myeloproliferative Neoplasms (MPNs)
Prelude Therapeutics100 enrolled1 locationNCT07469891
Recruiting
Phase 1Phase 2
A Study of BGB-11417 in Participants With Myeloid Malignancies
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
BeiGene260 enrolled46 locationsNCT04771130
Recruiting
Phase 1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation290 enrolled13 locationsNCT06034002
Recruiting
Phase 1
Study of INCA036978 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation218 enrolled47 locationsNCT07441694
Recruiting
Phase 1Phase 2
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
Myelodysplastic SyndromeRecurrent Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center58 enrolled1 locationNCT04493138
Recruiting
Phase 1Phase 2
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Acute Myeloid Leukemia+3 more
M.D. Anderson Cancer Center97 enrolled1 locationNCT04140487
Recruiting
Phase 1
A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation186 enrolled31 locationsNCT06313593
Recruiting
Phase 1
A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation120 enrolled26 locationsNCT07008118
Recruiting
Phase 1
A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyeloproliferative Neoplasm+1 more
Dana-Farber Cancer Institute50 enrolled2 locationsNCT04024761
Recruiting
Phase 1
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
Hematopoietic and Lymphatic System NeoplasmAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+9 more
City of Hope Medical Center46 enrolled3 locationsNCT07020533
Recruiting
Phase 1
A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
Myeloproliferative Neoplasms
Incyte Corporation225 enrolled29 locationsNCT05936359
Recruiting
Phase 1Phase 2
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
Refractory Chronic Myelomonocytic LeukemiaChronic Myelomonocytic LeukemiaMyelodysplastic/Myeloproliferative Neoplasm+5 more
Uma Borate52 enrolled1 locationNCT06523556
Recruiting
Phase 1
Phase Ib Study of CD33 FPBMC in Patients With MRD+ AML or MDS
Acute Myeloid LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasm
University of Virginia23 enrolled1 locationNCT07270978
Recruiting
Phase 1Phase 2
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
Acute Myeloid LeukemiaHematopoietic and Lymphoid System NeoplasmMyelodysplastic Syndrome+3 more
M.D. Anderson Cancer Center96 enrolled4 locationsNCT03471260
Recruiting
Phase 1Phase 2
An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms
MyelofibrosisMyeloproliferative NeoplasmPolycythemia Vera+2 more
University of California, Irvine27 enrolled2 locationsNCT05123365
Recruiting
Phase 1
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
Acute Myeloid LeukemiaMyelodysplastic SyndromeRecurrent Myelodysplastic Syndrome+15 more
M.D. Anderson Cancer Center58 enrolled1 locationNCT03630991
Not Yet Recruiting
Phase 1
A Double-Blind, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZE74-0282 in Healthy Volunteers.
Myeloproliferative Neoplasms (MPN)
Eilean Therapeutics AU Pty Ltd (A subsidiary of Eilean Therapeutics LLC)40 enrolled1 locationACTRN12626000214336
Recruiting
Phase 1
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
Recurrent Chronic Myelomonocytic LeukemiaRefractory Chronic Myelomonocytic LeukemiaRecurrent Myelodysplastic/Myeloproliferative Neoplasm+3 more
Mayo Clinic25 enrolled1 locationNCT05549661
Recruiting
Phase 1
Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK [IMGN632]) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms
Acute Myeloid LeukemiaMyelodysplastic SyndromeMyeloproliferative Neoplasm+2 more
Fred Hutchinson Cancer Center30 enrolled1 locationNCT06034470
Recruiting
Phase 1
Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
Acute Myeloid LeukemiaLeukemiaMyelodysplastic Syndromes+3 more
Dana-Farber Cancer Institute15 enrolled2 locationsNCT06138587